Tri Locum Partners’s Ventyx Biosciences VTYX Stock Holding History

Tri Locum Partners’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-57,800	Closed	-$1.9M	–	86
2023 Q2	$1.9M	Sell	57,800 -95,042	-62%	-$3.28M	0.7%	30
2023 Q1	$5.12M	Buy	+152,842	New	+$5.94M	1.56%	22
2022 Q4	–	Sell	-125,000	Closed	-$4.36M	–	92
2022 Q3	$4.36M	Buy	+125,000	New	+$2.77M	1.2%	28

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Tri Locum Partners's VTYX Position: Q3 2023 in Review

Tri Locum Partners sold out of Ventyx Biosciences (VTYX) in Q3 2023, closing a stake of 57,800 shares — an estimated $1.9M sold.

Tri Locum Partners first reported a position in VTYX in Q3 2022 and held it in 3 quarters. The position peaked at $5.12M in Q1 2023. 138 funds tracked by Wall St. Rank hold VTYX as of Q3 2023.

Tri Locum Partners reported no remaining Ventyx Biosciences position as of Q3 2023 after selling out during the quarter.
Tri Locum Partners sold 57,800 Ventyx Biosciences shares in Q3 2023, an estimated $1.9M.
Tri Locum Partners first reported a position in Ventyx Biosciences in Q3 2022 and held it in 3 quarters.
Tri Locum Partners's Ventyx Biosciences position peaked at $5.12M in Q1 2023.
138 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.